(opens in a new window)

Pablo Tebas, MD

Professor of Medicine (Infectious Diseases) at the Hospital of the University of Pennsylvania

  • Director & Principal Investigator, AIDS Clinical Trial Unit (ACTU) research site, University of Pennsylvania
  • Investigator of the Vaccine Trials Network, University of Pennsylvania
  • Attending Physician, Hospital of the University of Pennsylvania

Department: Medicine
Division: Infectious Diseases


Contact Information

Academic Address: 502 Johnson Pavilion
Clinical Office: 4 Perelman Center for Advanced Medicine, 3600 Civic Center Boulevard
Philadelphia, PA 19104
Office: 215-349-8092
Fax: 215-349-8011
Email: pablo.tebas@pennmedicine.upenn.edu


I3H Keywords

  • Vaccines

Publications

Pubmed Link


Links


Education

  • MD
    Universidad Autónoma de Madrid, Spain, 1985

Post-Graduate Training

  • Intern in Medicine
    Hospital Puerta de Hierro, Madrid, Spain, 1986 - 1987
  • Resident in Medicine
    Hospital Puerta de Hierro, Madrid, Spain, 1987 - 1991
  • Fellowship, Infectious Diseases
    Washington University in Saint Louis, Missouri, 1992 - 1995

Certifications

  • Spanish Board of Internal Medicine, 1992
  • American Board of Internal Medicine, Internal Medicine, 2014
  • American Board of Internal Medicine, Infectious Diseases, 2015

Description of Clinical Expertise

My clinical interest focus on the treatment of HIV infection and associated infections like hepatitis C. I have also a particular interest in the clinical manifestations and treatment of atypical mycobacterial infections. I also attend every year in the general infectious disease service of the hospital of University of Pennsylvania

Description of Research Expertise

My research interests center around the study of the complications of HIV and its treatment, and currently in the evaluation of strategies for the cure of HIV infection.
I am the director and the PI of the AIDS clinical trial unit of the University of Pennsylvania.
I am one of the founding members of the HIV Reservoirs and Viral Eradication (Cure) Transformative Science Group (TSG) of the AIDS clinical trial group. In addition to my ACTG work, I am involved (as PI of the clinical project) in several early phase trials of new compounds developed in conjunction with the NIH in several IPCP grants, including a Phase I study evaluating the antiviral activity of aprepitant (an NK-1R antagonist that down-regulates the expression of CCR5), a phase I study evaluating the immunogenicity of a therapeutic DNA vaccine administered by intramuscular electroporation in collaboration with David Weiner and several gene therapy studies evaluating the therapeutic use of lentiviral vectors in the management of HIV infection (including the use of VIRxSYS 496 –antisense approach-, the first in humans Sangamo’s zinc finger nuclease for CCR5 edition, in collaboration with Dr. Carl June.

Description of ITMAT Expertise

Dr. Tebas is involved in clinical trials evaluating new therapies for HIV infection including gene therapy and therapeutic DNA vaccines. His research interests include antiretroviral therapy, treatment of virologic failures, simplification strategies as well studying the metabolic complications associated with antiretroviral treatment.

Selected Publications

  • Conway, B., Tebas, P., Slama, L. : Understanding the clinical implications of low-level viremia in ART-treated individuals AIDS 39(11) : 1656-1657, September 2025
  • Nadig, N., Bhimraj, A., Cawcutt, K., Chiotos, K., Dzierba, A. L., Kim, A. Y., Martin, G. S., Pearson, J. C., Shumaker, A. H., Baden, L. R., Bedimo, R., Cheng, V. C., Chew, K. W., Daar, E. S., Glidden, D. V., Hardy, E. J., Johnson, S., Li, J. Z., MacBrayne, C., Nakamura, M. M., Riley, L., Shafer, R. W., Shoham, S., Tebas, P., Tien, P. C., Loveless, J., Falck-Ytter, Y., Morgan, R. L., Gandhi, R. T. : 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Abatacept Clin Infect Dis September 2025
  • Nadig, N., Bhimraj, A., Cawcutt, K., Chiotos, K., Dzierba, A. L., Kim, A. Y., Martin, G. S., Pearson, J. C., Shumaker, A. H., Baden, L. R., Bedimo, R., Cheng, V. C., Chew, K. W., Daar, E. S., Glidden, D. V., Hardy, E. J., Johnson, S., Li, J. Z., MacBrayne, C., Nakamura, M. M., Riley, L., Shafer, R. W., Shoham, S., Tebas, P., Tien, P. C., Loveless, J., Falck-Ytter, Y., Morgan, R. L., Gandhi, R. T. : 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Vilobelimab Clin Infect Dis August 2025
  • Nadig, N., Bhimraj, A., Cawcutt, K., Chiotos, K., Dzierba, A. L., Kim, A. Y., Martin, G. S., Pearson, J. C., Shumaker, A. H., Baden, L. R., Bedimo, R., Cheng, V. C., Chew, K. W., Daar, E. S., Glidden, D. V., Hardy, E. J., Johnson, S., Li, J. Z., MacBrayne, C., Nakamura, M. M., Riley, L., Shafer, R. W., Shoham, S., Tebas, P., Tien, P. C., Loveless, J., Falck-Ytter, Y., Morgan, R. L., Gandhi, R. T. : 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Infliximab Clin Infect Dis August 2025
  • Bhimraj, A., Falck-Ytter, Y., Baden, L. R., Bedimo, R., Cawcutt, K., Cheng, V. C., Chew, K. W., Chiotos, K., Daar, E. S., Dzierba, A. L., Glidden, D. V., Hardy, E. J., Johnson, S., Kim, A. Y., Li, J. Z., MacBrayne, C., Martin, G. S., Nadig, N., Nakamura, M. M., Pearson, J. C., Riley, L., Shafer, R. W., Shoham, S., Shumaker, A. H., Tebas, P., Tien, P. C., Loveless, J., Morgan, R. L., Gandhi, R. T. : 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness Clin Infect Dis August 2025
  • Wei, Y., Ma, H. K., Wong, M. E., Back, H., Papasavvas, E., Mounzer, K., Aberra, F., Morgenstern, R., Tebas, P., Konnikova, L., Montaner, L. J., Ho, Y. C. : Transcription factor BACH2 shapes tissue-resident memory T cell programs to promote HIV-1 persistence Immunity August 2025
  • Taiwo, B. O., Zheng, Y., Rodriguez, K., Burke, L., Reeves, J. D., Scarsi, K. K., Gama, L., Petropoulos, C. J., Belaunzaran-Zamudio, P. F., Wannamaker, P., D'Amico, R., Rathod, P., Bar, K., Tebas, P. : Phase 2 Trial of Long-Acting Cabotegravir and VRC07-523LS for Viral Suppression in Adults with HIV-1: ACTG A5357 Clin Infect Dis July 2025
  • McMyn, N. F., Varriale, J., Wu, H. W. S., Hariharan, V., Moskovljevic, M., Tan, T. S., Lai, J., Singhal, A., Lynn, K., Mounzer, K., Tebas, P., Montaner, L. J., Hoh, R., Yu, X. G., Lichterfeld, M., Simonetti, F. R., Kovacs, C., Deeks, S. G., Siliciano, J. M., Siliciano, R. F. : Factors associated with resistance of HIV-1 reservoir viruses to neutralization by autologous IgG antibodies J Clin Invest July 2025
  • Tebas, P. : Future of bNAbs in HIV Treatment Curr HIV/AIDS Rep 22(1) : 34, May 2025
  • Jadlowsky, J. K., Hexner, E. O., Marshall, A., Grupp, S. A., Frey, N. V., Riley, J. L., Veloso, E., McConville, H., Rogal, W., Czuczman, C., Hwang, W. T., Li, Y., Leskowitz, R. M., Farrelly, O., Karar, J., Christensen, S., Barber-Rotenberg, J., Gaymon, A., Aronson, N., Bernstein, W., Melenhorst, J. J., Roche, A. M., Everett, J. K., Zolnoski, S. A., McFarland, A. G., Reddy, S., Petrichenko, A., Cook, E. J., Lee, C., Gonzalez, V. E., Alexander, K., Kulikovskaya, I., Ramirez-Fernandez, A., Minehart, J. C., Ruella, M., Gill, S. I., Schuster, S. J., Cohen, A. D., Garfall, A. L., Shah, P. D., Porter, D. L., Maude, S. L., Levine, B. L., Siegel, D. L., Chew, A., McKenna, S., Lledo, L., Davis, M. M., Plesa, G., Herbst, F., Stadtmauer, E. A., Tebas, P., DiNofia, A., Haas, A., Haas, N. B., Myers, R., O'Rourke, D. M., Svoboda, J., Tanyi, J. L., Aplenc, R., Jacobson, J. M., Ko, A. H., Cohen, R. B., June, C. H., Bushman, F. D., Fraietta, J. A. : Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies Nat Med 31(4) : 1134-1144, April 2025